Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.164 SNIP: 0.041 CiteScore™: 0.18

ISSN Imprimer: 2151-8017
ISSN En ligne: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2014008368
pages 219-239

Bacterial Toxins in Cancer Immunotherapy

Irena Adkins
Sotio a.s., Prague, Czech Republic; and Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
Lenka Sadilkova
Sotio a.s., Prague, Czech Republic; and Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
Lenka Palova-Jelinkova
Sotio a.s., Prague, Czech Republic; and Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

RÉSUMÉ

Bacterial protein toxins perfected through evolution in pathogenic bacteria play an important role in infectious diseases and share the ability to target various intracellular proteins to modulate host immune responses. Several bacterial toxins and their nontoxic mutants have been intensively studied over the past decades to harness their abilities to enter host cells and deliver drugs for a direct elimination of cancer cells, to carry antigenic epitopes to stimulate adaptive T cell responses, and to boost immunity as adjuvants. Some of these toxins may be utilized in the diagnostics of cancer. Whereas the immunotherapeutic potential of some bacterial toxins is currently being evaluated in various phases of clinical cancer trials, the medical use of others needs to be further established. The major achievement in toxin-targeted immunotherapy is a derivative of lipopolysaccharide monophosphoryl lipid A, muramyl dipeptide derivative Mifamurtide, and Corynebacterium diphtheriae diphtheria toxin-based immunotoxin denileukin diftitox. However, some limitations of the use of bacterial toxins in human immunotherapy remain to be overcome.


Articles with similar content:

Phage Therapy against Streptococcus pneumoniae: Modern Tool to Control Pneumonia
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Muhammad Imran Qadir, Sahir Sajjad
Genetically Modified Aedes aegypti to Control Dengue: A Review
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Muhammad Shareef Masoud, Muhammad Qsim, Ijaz Rasul, Namrah Noor, Usman Ali Ashfaq, Muhammad Zubair Yousaf, Azfar Hussain
Structure and Biological Activity of Botulinum Neurotoxins and Application to Cancer Therapy
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 3-4
Ester Fernandez-Salas, Kei Roger Aoki
Dendritic Cells in Cancer Immunotherapy
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Matthias Gunzer, Stephan Grabbe
The Development of Monoclonal Antibodies for the Therapy of Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.8, 1998, issue 3-4
Ellen S. Vitetta, Larry Herrera, Roula A. Farah, Birgitta Clinchy